Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Tips to maintain and improve brain health

While there are still mysteries surrounding the fundamental process of memory, research has revealed activities that may enhance memory and promote overall brain health. John H. Byrne, Ph.D., professor and chairman of the Department of Neurobiology and Anatomy at the University of Texas Health Science Center at Houston (UTHealth) Medical School, studies the neuronal and molecular mechanisms underlying learning and memory. Here are three tips he offers for maintaining and improving brain health.

18 Aug 2010

Natick VNA offers checklist to help patients make informed choice of home health care provider

Home from the hospital already? As stays for hospital patients grow progressively shorter, even for procedures as serious as repairing a brain aneurysm or inserting a pacemaker, patients' need for highly skilled nursing care at home is growing. Indeed, every week, thousands of these patients are referred to home health care services.

17 Aug 2010

Jackson Laboratory to implement HighRes automated process for genotyping of laboratory mice

A highly accurate, automated process for managing the genotyping of laboratory mice is headed to Bar Harbor, Maine. In response to the increased demand for using transgenic mouse models and the requisite genotyping of such animals, The Jackson Laboratory will be implementing a HighRes Biosolutions automated process to improve the maintenance of their extensive and diverse mouse colonies.

17 Aug 2010

Psychological stress in middle age increases risk of dementia later in life

Psychological stress in middle age could lead to the development of dementia later in life, especially Alzheimer's disease, reveals research from the University of Gothenburg, Sweden. Based on data from a study which followed women for 35 years, this is the first research in Sweden to indicate a link between stress and dementia.

17 Aug 2010

Interinvest acquires common shares of Amorfix Life Sciences

On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.

17 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

Psychological stress in middle age can lead to dementia: Research

16 Aug 2010

Adverse effects in childhood lead to immune impairment later in life

The emotional pains we suffer in childhood can lead to weakened immune systems later in life, according to a new study.Based on this new research, the amount of this immune impairment even enhances that caused by the stress of caregiving later in life."What happens in childhood really matters when it comes to your immune response in the latter part of your life," explained Janice Kiecolt-Glaser, professor of psychology and psychiatry at Ohio State University. She explained her work at the annual meeting of the American Psychological Association in San Diego.

16 Aug 2010

Cox Business light-speed computer accelerates TGen’s molecular research

A Cox Business light-speed computer connection coupled with advanced, military-grade technology now provides Translational Genomics Research Institute (TGen) with the nation's fastest supercomputer link among life-sciences facilities.

16 Aug 2010

Cox Business light-speed computer connection provides TGen with fastest supercomputer link

A Cox Business light-speed computer connection coupled with advanced, military-grade technology now provides Translational Genomics Research Institute with the nation's fastest supercomputer link among life-sciences facilities.

13 Aug 2010

Researchers identify second type of complete sporadic disease

A new sporadic prion protein disease has been discovered. Variably protease-sensitive prionopathy, as it has been named, is the second type of complete sporadic disease to be identified since Creutzfeldt-Jakob disease was reported in the 1920s. The landmark finding from the National Prion Disease Pathology Surveillance Center at Case Western Reserve University is published in the August issue of Annals of Neurology.

13 Aug 2010

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Study finds lithium drugs not effective for amyotrophic lateral sclerosis treatment

A new study has found that the drug lithium is not effective in treating people with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. The research is published in the August 11, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Alectos Therapeutics collaborates with Merck for Alzheimer’s disease research

Alectos Therapeutics Inc. today announced a research collaboration with Merck, headquartered in Whitehouse Station, N.J., to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.

12 Aug 2010

Alzheimer's Disease News and Research

Further Reading

Tips to maintain and improve brain health

Natick VNA offers checklist to help patients make informed choice of home health care provider

Jackson Laboratory to implement HighRes automated process for genotyping of laboratory mice

Psychological stress in middle age increases risk of dementia later in life

Interinvest acquires common shares of Amorfix Life Sciences

Cortex second-quarter net loss decreases to $0.04 per share

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Nymox second-quarter net loss increases to $1.75 million

Psychological stress in middle age can lead to dementia: Research

Adverse effects in childhood lead to immune impairment later in life

Cox Business light-speed computer accelerates TGen’s molecular research

Cox Business light-speed computer connection provides TGen with fastest supercomputer link

Researchers identify second type of complete sporadic disease

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Study finds lithium drugs not effective for amyotrophic lateral sclerosis treatment

Intellect Neurosciences receives patent for insulin sensitizer drugs

Alectos Therapeutics collaborates with Merck for Alzheimer’s disease research

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News